General Nurse Practitioner News

NP

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nakabayashi M et al. – Ketoconazole has moderate activity as secondary hormonal therapy in patients with CRPC previously treated with taxane–based chemotherapy, although the TTP was short. Previous treatment with oestrogenic therapy is associated with a shorter TTP.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address